Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30372000 | 1.00 | FAAH (0.81) | FAAHMGLL | |
| SCHEMBL30371754 | 0.90 | FAAH (1.00) | FAAHMGLL | |
| SCHEMBL20567221 | 0.90 | FAAH (1.00) | FAAHMGLL | |
| Acetone SCHEMBL25405187 | 0.89 | FAAH (0.95) | FAAHMGLL | |
| SCHEMBL20566783 | 0.89 | FAAH (0.98) | FAAHMGLL | |
| SCHEMBL20567015 | 0.89 | FAAH (0.86) | FAAHMGLL | |
| Hydrochloric Acid SCHEMBL30371914 | 0.89 | FAAH (0.98) | FAAHMGLL | |
| Hydrochloric Acid SCHEMBL25406454 | 0.89 | FAAH (0.98) | FAAHMGLL | |
| SCHEMBL30420225 | 0.89 | FAAH (0.86) | FAAHMGLL | |
| SCHEMBL30420822 | 0.89 | FAAH (0.98) | FAAHMGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4426696-B1 | CRYSTALLINE FORMS OF A MONOACYLGLYCEROL LIPASE INHIBITOR | H LUNDBECK AS (DK) | 2026-05-06 | — | — | EP | disclosed |
| US-12152029-B2 | Crystalline forms of a MAGL inhibitor | H. LUNDBECK A/S (DK) | 2024-11-26 | — | — | US | disclosed |
| US-20230265095-A1 | CRYSTALLINE FORMS OF A MAGL INHIBITOR | LUNDBECK LA JOLLA RESEARCH CENTER, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230265095-A1 | CRYSTALLINE FORMS OF A MAGL INHIBITOR | LUNDBECK LA JOLLA RESEARCH CENTER, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230265095-A1 | CRYSTALLINE FORMS OF A MAGL INHIBITOR | LUNDBECK LA JOLLA RESEARCH CENTER, INC. | 2023-08-24 | — | — | US | disclosed |
| WO-2023078868-A1 | CRYSTALLINE FORMS OF A MONOACYLGLYCEROL LIPASE INHIBITOR | H. LUNDBECK A/S (DK) | 2023-05-11 | — | — | WO | disclosed |
| WO-2023078868-A1 | CRYSTALLINE FORMS OF A MONOACYLGLYCEROL LIPASE INHIBITOR | H. LUNDBECK A/S (DK) | 2023-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12152029-B2 | Crystalline forms of a MAGL inhibitor | MAG, MAGI3, PYM1 | FAAH 457/4885MGLL 7/4885 |
| US-20230265095-A1 | CRYSTALLINE FORMS OF A MAGL INHIBITOR | MAG, PYM1, MAGI3 | FAAH 252/4885MGLL 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.